Chinese medicine can effectively treat chronic atrophic gastritis
Chinese medicine can effectively treat chronic atrophic gastritis
January 10, 2018 Source: China Medical News
Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];
Image from the network
Chronic gastritis refers to various chronic gastric mucosal inflammatory lesions caused by different causes, and is a common disease of the digestive system.
With the rapid development of China's society and the changes in residents' lifestyles, the incidence of chronic gastritis in Chinese population is getting higher and higher, of which chronic atrophic gastritis (CAG) accounts for about 23.2%, non-atrophic gastritis (CSG, the original superficial Gastritis) accounts for about 59.3%. The clinical outcome of atrophic gastritis usually develops into intestinal metaplasia, precancerous lesions and gastric cancer, which seriously threaten the life and health of patients.
At present, the main problems in the chemotherapy treatment of chronic atrophic gastritis (CAG) are: first, the clinical treatment plan is complicated and the effect is limited; second, the incidence of adverse reactions is high and the safety is low; third, it is suitable for slow The drug for the principle of disease management is scarce. Therefore, the Zhejiang University Gastrointestinal Disease Research Institute organized experts to set up the CAG New Drug Research Group to find new drugs for effective treatment of CAG. In the previous screening study, the research team found that the innovative Chinese patent medicine Weierkang, which was listed in 1997, had a good clinical effect on chronic atrophic gastritis (CAG). Phase II clinical trial data of "Gangerkang treatment of chronic atrophic gastritis" showed that 30.0% CAG could be reversed to CSG, intestinal metaplasia disappearance rate was 39.1%, and dysplasia disappearance rate was 38.14%. In 2014, the team led by Prof. Jianmin Min from the Institute of Gastroenterology, Zhejiang University launched the research project “Evaluation of the efficacy of Weierkang on chronic atrophic gastritis (CAG)†and published in SCI (Science Citation Index) in November 2017. , referred to as "International Journal of Clinical and Experimental Medicine" in SCI), the International Journal of Clinical and Experimental Medicine.
The results of the study showed that the total effective rate of clinical symptom treatment of CAG patients was 65.2% after treatment with Weierkang for 3 months. After treatment with Weierkang for 6 months, the clinical symptomatic treatment efficiency of CAG patients was 85.3%; Compared with 3 months, the clinical improvement of patients after 6 months of treatment with Gastron was more obvious, and the difference was statistically significant (p<0.05). At 3 months and 6 months of treatment, the effective rate of improvement of inflammation was 26.2% and 42.5%, respectively. The effective rate of treatment of intestinal atrophy was 61.9% and 67.5%, respectively. Prolonged course of treatment could improve chronic atrophy. Gastric inflammation atrophy intestinal pathological state. The results of this clinical study showed that Weierkang can better improve the clinical symptoms of CAG patients, and in vitro experiments found that the active ingredients of Weierkang can affect the proliferation of gastric cancer cells and the expression of STAT1, STAT3 and NF-κB signaling pathways. . Therefore, it may be an important drug to reverse CAG, prevent intestinal metaplasia and precancerous lesions, and meet the principles of chronic disease management.
In order to further confirm the clinical value of Weierkang, in 2017, Zhejiang University Gastrointestinal Disease Research Institute once again launched a clinical research project to evaluate the efficacy of Weierkang on chronic atrophic gastritis.
Some patients completed the whole cycle calibration biopsy results showed that Weierkang can quickly improve clinical symptoms, reverse CAG to CSG, reverse intestinal metaplasia and dysplasia.
Original title: Institute of Gastroenterology, Zhejiang University: Chinese medicine can effectively treat chronic atrophic gastritis
Insulin Syringes Needle,Disable Syringe,Monoject Syringe,10 Ml Syringe
FOSHAN PHARMA CO., LTD. , https://www.forepharm.com